<DOC>
	<DOCNO>NCT01972789</DOCNO>
	<brief_summary>To evaluate compare two individualised ranibizumab treatment regimen , differentiate definition disease activity determine treatment interval next injection . The result use generate recommendation intensive versus relax treatment approach utilise within 'inject extend ' approach maximise patient outcome , reduce need potentially unnecessary intravitreal injection . This study also investigate genotypic expression response intravitreal injection ranibizumab two treatment arm . The study hypothesis intravitreal ranibizumab administer resolve IRF result visual acuity benefit clinically bad intravitreal ranibizumab administer completely resolve IRF SRF patient wet AMD .</brief_summary>
	<brief_title>Comparison Treatment Regimens Using Ranibizumab : Intensive ( Resolution Intra- Sub-retinal Fluid ) v Relaxed ( Resolution Primarily Intra-retinal Fluid ) Treatment .</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1 . Diagnosis subfoveal CNV secondary wet AMD without restriction lesion size , visual impairment exclusively due active wet AMD lesion . Active lesion characterise follow : abnormal retinal thickness , evidence intraretinal , subretinal subpigment epithelial fluid accumulation , confirm OCT ; presence intraretinal subretinal haemorrhage ; new leakage show FA ; CNV enlargement FA unless solely due dry , fibrotic staining ; visual acuity deterioration consider likely represent CNV . 2 . BCVA score Screening Baseline must 23 letter measure Early Treatment Diabetic Retinopathy Study ( ETDRS ) logMAR chart ( Snellen visual acuity equivalent 20/320 may use alternative Screening ) . 1 . Any active periocular ocular infection inflammation ( e.g. , blepharitis , conjunctivitis , keratitis , scleritis , uveitis , endophthalmitis ) time Screening Baseline . 2 . Uncontrolled glaucoma ( intraocular pressure [ IOP ] â‰¥30 mm Hg medication ) time Screening Baseline . 3 . Neovascularisation iris neovascular glaucoma time Screening Baseline . 4 . Visually significant cataract , aphakia , severe vitreous haemorrhage , rhegmatogenous retinal detachment , proliferative diabetic retinopathy CNV cause wet AMD time screen baseline . 5 . Structural damage within 0.5 disc diameter centre macula ( e.g. , vitreomacular traction , epiretinal membrane , scar , laser burn , foveal atrophy ) time screen investigator 's opinion could preclude visual function improvement treatment . 6 . Treatment antiangiogenic drug ( include antiVEGF agent ) prior Baseline study eye ( allow fellow eye ) . 7 . Any intraocular procedure ( include YtriumAluminium Garnet capsulotomy ) within 2 month prior Baseline anticipate within next 6 month follow Baseline th study eye ( allow fellow eye ) . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Subfoveal choroidal neovascularization ( CNV ) ; wet age-related macular degeneration ( AMD ) ; inject extend ; retinal fluid</keyword>
</DOC>